Chemotherapy for Lung Cancer in Haemodialysis Patients
Author Information
Author(s): Watanabe R, Takiguchi Y, Moriya T, Oda S, Kurosu K, Tanabe N, Tatsumi K, Nagao K, Kuriyama T
Primary Institution: Chiba University
Hypothesis
Can full-dose combination chemotherapy with cisplatin and etoposide be safely administered to haemodialysis patients with lung cancer?
Conclusion
Full-dose combination chemotherapy with cisplatin and etoposide is feasible and tolerable for lung cancer patients undergoing haemodialysis.
Supporting Evidence
- Partial response was obtained in four of the five cases.
- All five haemodialysis patients experienced anaemia and neutropenia.
- Toxicity was well tolerated among the patients.
- Pharmacokinetics data suggested the safety of full-dose chemotherapy.
- Dialysability of cisplatin was efficient in haemodialysis patients.
Takeaway
Doctors tested a special cancer treatment for patients on kidney dialysis and found it worked well without too many side effects.
Methodology
A dose escalation study was conducted with five haemodialysis patients and three patients with normal renal function to monitor pharmacokinetics and toxicity.
Potential Biases
Potential bias due to the small number of patients and the lack of a control group.
Limitations
The study was limited to a small sample size of five patients.
Participant Demographics
Five patients with lung cancer and renal insufficiency undergoing haemodialysis, including three with stage IV adenocarcinoma and two with small-cell lung carcinoma.
Statistical Information
P-Value
0.024 and 0.011
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website